Parallel Advisors, LLC Biotechnology

Parallel Advisors, LLC

$4.18 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ALVR Allovir, Inc.	$40.9M	$0 0.0% of portfolio	1,145	Q4 2022 Reduced 10.55%
ALT Altimmune, Inc.	$337M	$0 0.0% of portfolio	40	Q3 2022 Reduced 90.91%
AMRN Amarin Corp Plcuk	$222M	$0 0.0% of portfolio	200	Q4 2022 Reduced 87.58%
ACLX Arcellx, Inc.	$3.02B	$0 0.0% of portfolio	10	Q3 2024 New
ARDX Ardelyx, Inc.	$801M	$0 0.0% of portfolio	104	Q3 2024 New
BCRX Biocryst Pharmaceuticals Inc	$1.43B	$0 0.0% of portfolio	124	Q3 2024 Added 33.33%
CARA Cara Therapeutics, Inc.	$255M	$0 0.0% of portfolio	4	Q3 2023 Reduced 95.51%
CPRX Catalyst Pharmaceuticals, Inc.	$2.25B	$0 0.0% of portfolio	13	Q3 2023 Reduced 91.5%
CLDX Celldex Therapeutics, Inc.	$1.14B	$0 0.0% of portfolio	22	Q2 2023 Reduced 8.33%
KDNY Chinook Therapeutics, Inc.	$0	$0 0.0% of portfolio	5	Q3 2023 Reduced 80.77%
CDXS Codexis, Inc.	$288M	$0 0.0% of portfolio	200	Q3 2023 Reduced 50.0%
CRVS Corvus Pharmaceuticals, Inc.	$254M	$0 0.0% of portfolio	20	Q2 2021 New
EDIT Editas Medicine, Inc.	$86.6M	$0 0.0% of portfolio	60	Q3 2024 Reduced 74.47%
FULC Fulcrum Therapeutics, Inc.	$227M	$0 0.0% of portfolio	170	Q2 2024 Added 126.67%
HRTX Heron Therapeutics, Inc.	$184M	$0 0.0% of portfolio	200	Q3 2023 Reduced 75.7%
IMUX Immunic, Inc.	$32.1M	$0 0.0% of portfolio	2	Q2 2019 New
IMNM Immunome Inc.	$127M	$0 0.0% of portfolio	28	Q2 2024 New
IMVT Immunovant, Inc.	$3.55B	$0 0.0% of portfolio	0	Q3 2024 New
NTLA Intellia Therapeutics, Inc.	$775M	$0 0.0% of portfolio	6	Q3 2024 Reduced 84.62%
ITOS I Teos Therapeutics, Inc.	$276M	$0 0.0% of portfolio	11	Q3 2024 Reduced 79.25%
JANX Janux Therapeutics, Inc.	$1.95B	$0 0.0% of portfolio	22	Q3 2024 New
KALV Kal Vista Pharmaceuticals, Inc.	$193M	$0 0.0% of portfolio	68	Q3 2024 New
KYMR Kymera Therapeutics, Inc.	$2.09B	$0 0.0% of portfolio	21	Q3 2024 Added 162.5%
LGND Ligand Pharmaceuticals Inc	$1.79B	$0 0.0% of portfolio	2	Q1 2023 Reduced 50.0%
MOR Morpho Sys Ag	$0	$0 0.0% of portfolio	1,492	Q3 2023 Added 63.46%
NAVB Navidea Biopharmaceuticals, Inc.	$0	$0 0.0% of portfolio	350	Q1 2020 New
NUVL Nuvalent, Inc.	$3.29B	$0 0.0% of portfolio	9	Q3 2024 New
OCUL Ocular Therapeutix, Inc	$632M	$0 0.0% of portfolio	1	Q3 2024 New
PRTA Prothena Corp Public LTD CO	$612M	$0 0.0% of portfolio	0	Q3 2024 Sold Out
CRTX Cortexyme, Inc.	$70.5M	$0 0.0% of portfolio	295	Q2 2024 Reduced 5.14%
RGNX Regenxbio Inc.	$325M	$0 0.0% of portfolio	50	Q2 2023 Reduced 7.41%
RYTM Rhythm Pharmaceuticals, Inc.	$3.13B	$0 0.0% of portfolio	19	Q3 2024 Added 280.0%
SVRA Savara Inc	$317M	$0 0.0% of portfolio	193	Q3 2024 New
SRRK Scholar Rock Holding Corp	$2.09B	$0 0.0% of portfolio	61	Q3 2023 New
SLDB Solid Biosciences Inc.	$28.2M	$0 0.0% of portfolio	7	Q2 2024 Added 16.67%
TSHA Taysha Gene Therapies, Inc.	$85.1M	$0 0.0% of portfolio	280	Q2 2024 New
TPST Tempest Therapeutics, Inc.	$9.59M	$0 0.0% of portfolio	235	Q3 2024 Reduced 0.42%
VNDA Vanda Pharmaceuticals Inc.	$260M	$0 0.0% of portfolio	87	Q2 2023 Added 188.5%
VERA Vera Therapeutics, Inc.	$1B	$0 0.0% of portfolio	15	Q3 2024 New
VERV Verve Therapeutics, Inc.	$331M	$0 0.0% of portfolio	23	Q3 2024 New
VIRX Viracta Therapeutics, Inc.	$7.14M	$0 0.0% of portfolio	8	Q1 2021 New
VRDN Viridian Therapeutics, Inc.\De	$726M	$0 0.0% of portfolio	28	Q3 2024 New
WVE Wave Life Sciences Ltd.	$1B	$0 0.0% of portfolio	95	Q1 2023 New
YMAB Y M Abs Therapeutics, Inc.	$301M	$0 0.0% of portfolio	18	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.